ArticleNeuropsychiatric disease and treatment2010
Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.
Article in Neuropsychiatric disease and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis.Annals of clinical and translational neurology · 2019Pooled it
- Molecular Basis of GABA Aminotransferase Inhibition in Epilepsy: Structure, Mechanisms, and Drug Development.Current issues in molecular biology · 2025Review
- Optimized Treatment for Infantile Spasms: Vigabatrin versus Prednisolone versus Combination Therapy.Journal of clinical medicine · 2019Article
- An Updated List of Neuromedicinal Plants of Pakistan, Their Uses, and Phytochemistry.Evidence-based complementary and alternative medicine : eCAM · 2019Review
- West Syndrome: A Review and Guide for Paediatricians.Clinical drug investigation · 2018Review
- CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.Epilepsia · 2014Article
- Clinical trial of vigabatrin as adjunctive therapy in children with refractory epilepsy.Iranian journal of pediatrics · 2013Article
- Latest American and European updates on infantile spasms.Current neurology and neuroscience reports · 2013Review
- Infantile spasms: treatment challenges.Current treatment options in neurology · 2012Article
- The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.Journal of medicinal chemistry · 2012Article
- Safety and efficacy of vigabatrin for the treatment of infantile spasms.Journal of central nervous system disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partial epilepsy, represents an important advance for patients with difficult-to-manage epilepsy. This review summarizes the complex history, chemistry, and pharmacology, as well as the clinical data leading to the approval of vigabatrin for infantile spasms in the US. The long path to its approval reflects the visual system and white matter toxicity concerns with this agent. This review provides a brief description of these concerns, and the regulatory safety monitoring and mitigation systems that have been put in place to enhance benefit over risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.